Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Advancements in drug development
3.2.1.2 Improved diagnostic techniques
3.2.1.3 Growing disease awareness initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Competition from alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021–2032 ($ Mn)
5.1 Key trends
5.2 Hypomethylating drugs
5.3 Immune therapy drugs
5.3.1 Immunomodulatory drugs
5.3.2 Immunosuppressive drugs
5.4 Antianemics drugs
5.5 Thrombopoietin receptor agonists
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021–2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021–2032 ($ Mn)
7.1 Key trends
7.2 Refractory anemia with excess blasts (RAEB)
7.3 Refractory cytopenia with multilineage dysplasia (RCMD)
7.4 Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)
7.5 Other cancer types
Chapter 8 Market Estimates and Forecast, By Medication, 2021–2032 ($ Mn)
8.1 Key trends
8.2 Branded
8.3 Generic
Chapter 9 Market Estimates and Forecast, By Age Group, 2021–2032 ($ Mn)
9.1 Key trends
9.2 Above 80
9.3 70-79
9.4 60-69
9.5 50-59
9.6 40-49
9.7 Below 40
Chapter 10 Market Estimates and Forecast, By End-user, 2021–2032 ($ Mn)
10.1 Key trends
10.2 Healthcare providers
10.2.1 Hospitals
10.2.2 Specialty clinics
10.3 Patients
10.4 Other end-users
Chapter 11 Market Estimates and Forecast, By Region, 2021–2032 ($ Mn)
11.1 Key trends
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Netherlands
11.3.7 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Argentina
11.5.4 Rest of Latin America
11.6 Middle East and Africa
11.6.1 Saudi Arabia
11.6.2 South Africa
11.6.3 UAE
11.6.4 Rest of Middle East and Africa
Chapter 12 Company Profiles
12.1 Amgen Inc.
12.2 Astex Pharmaceuticals, Inc.
12.3 Bristol-Myers Squibb Company (Celgene Corporation)
12.4 Cipla Limited
12.5 Dr. Reddy's Laboratories Inc.
12.6 Hikma Pharmaceuticals PLC
12.7 Johnson & Johnson Services, Inc.
12.8 Lupin Limited
12.9 Otsuka America Pharmaceutical, Inc.
12.10 Pfizer, Inc.
12.11 Sandoz
12.12 Shilpa Medicare Limited
12.13 Sun Pharmaceutical Industries, Inc.
12.14 Takeda Pharmaceutical Company Limited
12.15 Teva Pharmaceutical Industries Ltd
Myelodysplastic Syndrome Drugs Market Size
Myelodysplastic Syndrome Drugs Market size was valued at USD 2.8 billion in 2023 and is estimated to grow at 8% CAGR from 2024 to 2032. The market is experiencing dynamic growth driven by the increasing incidence of MDS, particularly among the aging population, this has risen the demand for effective treatments.
For instance, according to the American Cancer Society, approximately 10,000 new cases of MDS are diagnosed annually in the U.S. alone, with a higher incidence in individuals over 60 years old. As a result, the adoption of myelodysplastic syndrome (MDS) drugs is increasing. Moreover, the rise in technological advancement in diagnostic techniques have improved early detection of MDS, which can lead to earlier and more effective treatment, thus increasing the demand for MDS drugs. Furthermore, strategic collaborations and partnerships among biotech firms and research institutions are accelerating the development of new therapies, thereby contributing the market growth.
MDS drugs refer to the pharmaceutical treatments used to manage and treat myelodysplastic syndromes (MDS), which are a group of disorders caused by poorly formed or dysfunctional blood cells. MDS affects the bone marrow's ability to produce healthy blood cells, leading to problems like anemia, infections, and bleeding. This market includes a wide range of therapeutic agents such as hypomethylating agents, immunomodulatory drugs, anti-anemics drugs etc.
U.S. Contraceptives Market
Contraceptives Market
Mucosal Atomization Device Market
Ureteral Stents Market